Malonyl-CoA inhibits CPT1A activity through allosteric inhibition and in a concentration-dependent manner, and the C-termini of CPT1A served as the malonyl-CoA binding site (Rao et al., 2011)
In reality, thats not entirely true
The dose-findings studies reported here not only documented the superior efficacy of GLP1/E in the management of metabolic alterations in our obese PCOS model, including lowering body weight and adiposity, as well as improvement of glucose handling and insulin resistance, but also highlighted a non-monotonic effect of this dual agonist in PNA mice, with optimal effects being achieved with submaximal doses
These factors may include your diet and medical condition
Methods A previously developed, two-compartment pharmacokinetic model, based on subcutaneous and intravenous semaglutide, was extended to include data from six oral semaglutide trials conducted in either healthy volunteers or subjects with renal or hepatic impairment
The trade-off is speed